Hangzhou Tigermed Consulting Co., Ltd (SHE:300347)

China flag China · Delayed Price · Currency is CNY
59.29
-1.41 (-2.32%)
Sep 26, 2025, 3:04 PM CST
-2.32%
Market Cap48.44B
Revenue (ttm)6.50B
Net Income (ttm)295.63M
Shares Out855.14M
EPS (ttm)0.35
PE Ratio171.80
Forward PE42.27
Dividend0.30 (0.51%)
Ex-Dividend DateJun 17, 2025
Volume10,384,552
Average Volume14,171,752
Open60.09
Previous Close60.70
Day's Range58.76 - 60.98
52-Week Range41.61 - 82.79
Beta0.82
RSI41.66
Earnings DateOct 27, 2025

About SHE:300347

Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People’s Republic of China and internationally. It operates through Clinical Trial Solutions; and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monito... [Read more]

Sector Healthcare
Founded 2004
Employees 10,185
Stock Exchange Shenzhen Stock Exchange
Ticker Symbol 300347
Full Company Profile

Financial Performance

In 2024, SHE:300347's revenue was 6.60 billion, a decrease of -10.58% compared to the previous year's 7.38 billion. Earnings were 405.14 million, a decrease of -79.99%.

Financial Statements

News